Latest Breaking News On - க்யாத்லீந் க்வின் - Page 8 : comparemela.com

    · New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults · If results are positive, Phase 3 study to start in Q2 2021, with vaccine expected to be available in Q4 2021 · In parallel, development work on new SARS-CoV-2 variants underway     Sanofi and GlaxoSmithKline (GSK) announced today the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate.   Over the past few weeks, our teams have worked to refine the antigen formulation of our recombinant-protein vaccine, based on learnings from our initial Phase 1/2 study. said Thomas Triomphe, Executive Vice President and Head of Sanofi Pasteur. We are confident that our vaccine candidate has strong potential

United statesUnited kingdomUnited kingdom generalCity ofSimon mooreSarah elton farrKathleen quinnJeff mclaughlinSimon steelSonya ghobrialThomas triompheSanofi pasteurRoger connorJames dodwellKristen neeseUnited state biomedical advanced research